We exploit various screening techniques
to generate new antibodies for educing "Genome Super Power",
hidden informations in the genome.
TOPICS
2020.12.01
We have delivered a press release regarding “Anti-Cripto-1 antibody”.
Press Release: Joint development of antibody drug targeting cancer stem cells for the start of clinical trials
Distributor: Click here for the CDW Holding Limited website.
2020.09.09
Obtained a patent for “Anti-human Cripto-1 antibody”.
2018.01.09
Our website launch!
For Reseachers
For the future and leading edge of life science
We research and develop with modern installation on respect and inherit the intention of the late professor emeritus of Keio University, Nobuyoshi Shimizu.
We strongly aid your research going into unknown fields with our new antibodies. They will be gererated from the original phage-displayed antibody library surported by reliable screening methodology based on the antigen characteristics.
Atsushi Takayanagi, ph.D. CEO & CTO
Our Technology
GSP Enterprise, Inc., is a research institute following in the footsteps of the late Professor Emeritus Nobuyoshi Shimizu, a leading expert in genome research.
Prof. Shimizu was on the front line of global genome research, called the Human Genome Project, leading both the world and Japan. In 1999 he was able to decipher the whole human chromosome 22. This was one of the greatest achievements on the genome project. In the following year, he succeeded in deciphering the chromosome 21, and the chromosome 8 in 2003. Prof. Shimizu not only furthered genome analysis, but also discovered causative genes such as Parkinson's disease, autoimmune disease, hearing loss, glaucoma, etc. in addition to analyzing their function.
In 2007, Professor Shimizu retired from Keio University School of Medicine. His passion for research towards elucidating the genome super power (GSP) in the genome continued until just before his decease in 2015, at the age of 74.
Our company was established to support his research and researchers assisting his research. We will expand his work into the future.
Our Technology
Our antibody library is scFv (single-chain Fv) antibody-displaying phage library. The repertoire of antibody gene is more than 13-14th power of 10. Construction of a new Fab antibody library with spectacularly improvement is in progress.
Recent Works
We develop antibodies against tumors, virus and others.
About Us
Company Profile
Name: GSP Enterprise, Inc.
Establishd: Apr. 1, 2008
CEO&CTO: Junya Imai
Advisor: Yoshiko Shimizu
Address: 12F, Kintetsu Shin-Namba Bldg.,1-4-38,
Minato-machi, Naniwa-ku, Osaka, 556-0017, Japan
Business:
1. Antibody development utilized the original antibody library
2. Contract of antibody screening
3. Production of recombinant antibodies
4. Development of new antibody libraries
5. Distribution of reagents for antibody screening
6. Collaborative developments